Clinical Trial

A Study to Evaluate the Effects of the Combination of GI-102 With GIB-7 on Biomarkers of Aging in Healthy Adults and Cancer Survivors

Study acronym: GIANTS-1
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 26, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
This Phase 2a clinical study (GIANTS-1) aims to evaluate a novel dual-combination strategy using GI-102 and GIB-7 to address key pathological features of aging, including immunosenescence (the aging of the immune system), metabolic dysfunction, and gut-brain-muscle axis dysregulation.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-14.
Trial Details
NCT Number NCT07363057
Lead Sponsor GI Innovation, Inc.
Collaborators: GILongevity
Conditions Cancer Survivors, Healthy Participant, Elderly
Enrollment 15 participants
Start Date 2026-01
Primary Completion 2026-05 (estimated)
Study Completion 2026-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-26